Ozanimod shows promise for inducing and maintaining remission in ulcerative colitis
In short: A phase 3 randomized trial of 645 patients found that the drug ozanimod was more effective than a placebo for treating moderately to severely active ulcerative colitis. Researchers observed that patients receiving the treatment achieved significantly higher rates of clinical remission during both the initial 10-week induction phase and the subsequent 52-week maintenance period.
The study used a double-blind, placebo-controlled design to track clinical, endoscopic, and histologic outcomes. While the results showed significant improvements in remission and response rates, the researchers noted that elevated liver aminotransferase levels were more frequent in the ozanimod group, and the incidence of infection was higher during the maintenance phase compared to placebo.
Why it matters: Ozanimod may serve as an effective option for both starting and maintaining remission in ulcerative colitis patients.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Sandborn et al. (2021). Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine.
To cite this card, link to https://intellectplus.co.uk/app/science-research-ozanimod-shows-promise-for-inducing-and-maintaining-remissio.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Science · Latest · A–Z · All topics